Apollomics Inc.’s APL-101 Study: A Potential Game-Changer in Cancer Treatment

Apollomics Inc. ((APLM)) announced an update on their ongoing clinical study.

Apollomics Inc. is conducting a Phase 1/2 study titled ‘Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors’. The study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of APL-101 in treating various cancers, including non-small cell lung cancer (NSCLC) with specific genetic mutations. This research is significant as it targets MET gene alterations, which are implicated in cancer progression.

The intervention being tested is APL-101, an oral capsule drug designed to treat cancers with MET gene alterations. It is being tested both as a monotherapy and in combination with EGFR inhibitors for certain NSCLC patients.

The study is interventional, non-randomized, and follows a single-group assignment model without masking. Its primary purpose is treatment, focusing on assessing the drug’s impact on specific cancer types.

The study began on June 1, 2017, with its primary completion expected by June 24, 2025. The last update was also submitted on June 24, 2025. These dates are crucial as they mark the study’s progress and timeline for potential results.

The update on this study could influence Apollomics Inc.’s stock performance and investor sentiment, as successful outcomes may enhance the company’s market position. Investors should also consider the competitive landscape, as advancements in cancer treatments are highly competitive.

The study is ongoing, with further details available on the ClinicalTrials portal.